

PAPER

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *RSC Adv.*, 2019, 9, 33170Received 11th September 2019
Accepted 9th October 2019

DOI: 10.1039/c9ra07288h

rsc.li/rsc-advances

Heterocyclic iodoniums as versatile synthons to approach diversified polycyclic heteroarenes†

Daqian Zhu,^{ab} Zhouming Wu,^a Liyun Liang,^a Yameng Sun,^a Bingling Luo,^a
Peng Huang^a and Shijun Wen^{id}*^a

Polycyclic heteroarenes are important scaffolds in the construction of pharmaceuticals. We have previously developed a series of novel heterocyclic iodoniums. In our current work, these unique iodoniums were employed to construct various complex polycyclic heteroarenes with structural diversity *via* tandem dual arylations. As a result, indole, thiophene and triphenylene motifs were fused into these heterocycles with high molecular quality, which might provide promising fragments in drug discovery. Moreover, these heterocycles could be diversified at a late stage.

Introduction

Polycyclic heteroarenes are important scaffolds in the construction of pharmaceuticals.¹ Compared with polycyclic aromatic hydrocarbons, heterocycles exhibit improved solubility and bioavailability, which make them promising drug candidates.² Many heterocycles are reported as kinase inhibitors, anti-infective and antibacterial agents (Fig. 1). Thus, the design and synthesis of polycyclic heteroarenes are highly demanded.

Tandem reactions enable rapid access to complex molecules, avoiding tedious purification steps and minimizing chemical waste generation.³ As a paradigm of tandem reactions, dual arylations with cyclic diphenyl iodoniums (CDPIs) are employed to construct various polycycles, such as acridine,⁴ carbazole,⁵ fluorene,⁶ phenanthrene,⁷ and dibenzothiophene.⁸ These obtained polycycles are often heavily hydrocarbon oriented. In the drug discovery field, heterocyclic frameworks are crucial to gain druggability. Heterocyclic iodoniums (HCIs) could be promising alternative reagents to replace CDPIs for the potential construction of heterocycles (Scheme 1). However, HCIs are under-explored and only few of them have been reported.⁹ Very recently, we have developed a series of new HCIs,¹⁰ and now we wish to fully investigate their synthetic application potentials to obtain diverse heterocycles *via* tandem transformations.

Indole-fused polyheterocycles are privileged structural motifs.¹¹ Despite various strategies to generate these complex

molecules, there still lacks a general approach to rapidly build libraries of indole-fused heterocycles with a skeleton diversity. In our previous work, dual aminations of CDPIs led to the construction of functionalized *N*-substituted carbazoles.^{5b} Inspired by this work, we hypothesized the amination strategy could be extended to construct indole-fused heterocycles if HCIs were used as starting materials to replace CDPIs. In this current work, we thoroughly investigated tandem dual aminations of HCIs with various amines to produce indole-fused polycyclic scaffolds. In addition, the annulations of HCIs with triethylammonium *N*-benzyldithiocarbamate and 2-chlorobenzoic acid were also fully investigated. These transformations will provide efficient pathways for rapid generation of complex heterocycles with a structural diversity.

Results and discussion

Chromone is a privileged motif for drug design and discovery in the field of medicinal chemistry.¹² Thus, we commenced the dual-amination transformation using chromone embedded HCIs **1a–1e** as building blocks (Scheme 2). Under catalytic mediation of Cu(OAc)₂, *p*-anisidine underwent dual arylations to complete the amination.

As a result, the desired chromone-fused indoles were obtained at modest to good yields (**3a–3e**). Then, we explored the substrate scope and generality of other HCIs with different heterocyclic motifs. Thiochromone-fused indole was obtained at a moderate yield (**3f**). Quinoline, isoquinoline and coumarin are important building blocks for naturally occurring products and pharmaceuticals. These unique heterocyclic fused indoles could be also assembled efficiently (**3g–3m**). The HCIs bearing chlorine atom usually gave low yields (**3a** vs. **3c**, **3g** vs. **3i**). Meanwhile, the construction of thieno[3,2-*b*]indole (**3n**) was realized, providing a concise method to obtain thiophene-containing materials.

^aState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, China. E-mail: wenshj@sysucc.org.cn

^bSchool of Pharmacy, Guangdong Pharmaceutical University, 280 Waihuan East Road, Guangzhou 510006, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra07288h







Fig. 1 Selected examples of heterocyclic natural products and pharmaceuticals.

Subsequently, the substrate scope of this reaction was further examined on variation of the amines (Scheme 3). Like *p*-anisidine, other arylamines bearing different functional groups also enabled their incorporation into chromone-containing HCl **1a** to provide diverse chromone-fused indoles (**4a–4i**). It should be noted that the intact bromo or iodo in products **4e** and **4f** could serve as a potential transformation platform for late-stage diversification. Meanwhile, arylamines with electron-deficient groups disfavored these reactions and provided the products in low yields (**4h–4j**). Amines tethering on pyridine and quinoline also performed smoothly (**4j–4k**). However, additional CuI (0.1 equiv.) was required while alkyl amines were used. Under the modified condition, the desirable products were successfully obtained (**4l–4o**). Again, pyridine motif in the alkylamine did not disrupt the reaction (**4l**).

Sulfur containing heterocycles have found considerable utility particularly in material science because of high resonance energy of sulfur atom.¹³ Traditional methods for the introduction of sulfur suffer from several disadvantages such as catalyst poisoning, over-oxidization, and stinky smell. Using our recently discovered odor-free triethylammonium *N*-benzylthiocarbamate (**M1**) as the sulfur source donor,^{8a} reactions of HCIs and **M1** under mediation of copper sulfate could smoothly furnish benzothiophene-fused heterocyclic frameworks, including chromone (**5a**), quinoline (**5b**), isoquinoline (**5c**) and coumarin (**5d**), as shown in Scheme 4.


Decarboxylation of commercially available carboxylic acids is emerging as a novel strategy for aromatic functionalization.¹⁴ A pioneering work has recently been extended to decarboxylation of 2-chlorobenzoic acid for *in situ* generation of benzyne to




Scheme 1 Synthesis of polycyclic heteroarenes using HCIs.

construct triphenylenes.¹⁵ As counterparts of these hydrocarbons, the heteroatom-containing triphenylene analogues exhibit distinct chemical and physical properties.¹⁶ However, they have been so far less touched due to limited synthetic protocols. Thus, HCIs could be very promising synthons to construct such unique triphenylene. In our study, HCIs reacted with 2-chlorobenzoic acid to effectively afford the desirable annulated heterocycles containing chromone (**6a**), thiochromone (**6b**), or quinoline (**6c**), as shown in Scheme 5.

Finally, we have taken several applications to further demonstrate the robustness of these unique heterocyclic iodoniums as synthons (Scheme 6). Firstly, the copper-catalyzed




Scheme 2 Substrate scope of HCIs to synthesize heterocycle-fused indoles. Reaction conditions: **1** (0.1 mmol), *p*-anisidine (2.5 equiv.), *i*-PrOH/(CH₂OH)₂ (0.9/0.1 mL), refluxing, Ar, 16 h.




Scheme 3 Scope of amines reacting with **1a** to construct chromone-fused indoles. Reaction conditions: **1a** (0.1 mmol), amine (2.5 equiv.), *i*-PrOH/(CH₂OH)₂ (0.9/0.1 mL), refluxing, Ar, 16 h. ^aAdditional CuI (0.1 equiv.) added.


dual aminations of HCIs performed well in a gram-scale reaction without a compromised yield (Scheme 6a). The increasing emergence of drug resistance in treating diseases demands an urgent need to develop new drugs. One effective strategy has been pursued combining two different drugs to form a new



Scheme 4 Sulfur insertion of HCIs with triethylammonium *N*-benzylthiocarbamate **M1**. Reaction conditions: **1** (1 equiv.), **M1** (2 equiv.), CuSO_4 (0.1 equiv.), MeCN, 60 °C, Ar, 6 h.



Scheme 5 Annulation of 2-chlorobenzoic acid with HCIs. Reaction conditions: 2-chlorobenzoic acid (1 equiv.), **1** (1.2 equiv.), K_2CO_3 (2.2 equiv.), $\text{Pd}(\text{OAc})_2$ (0.1 equiv.), 1-methyl-2-pyrrolidinone, 140 °C, 16 h.



Scheme 6 (a) Scale-up synthesis of **4b** under the standard condition. (b) Synthesis of drug-like hybrids and late-stage diversification with **1a** and **1p**. Reaction conditions: (i)–(iii) **1a** or **1p** (0.2 mmol), amine (2.5 equiv.), Na_2CO_3 (3 equiv.), $\text{Cu}(\text{OAc})_2$ (0.1 equiv.), *i*-PrOH/(CH₂OH)₂ (1.8/0.2 mL), Ar, refluxing, 16 h. (iv) AcCl (1.2 equiv.), Et_3N (2.0 equiv.), CH_2Cl_2 , rt; PPA (0.2 mL), POCl_3 (10 equiv.), 120 °C. (v) TsOH -H₂O (0.1 equiv.), EtOH, reflux. ^aAdditional CuI (0.1 equiv.) added.

hybrid molecule.¹⁷ Herein, tryptamine, a serotonin receptor agonist, and an amine derived from androstrone (an endogenous steroid hormone) were employed to react with chromone-fused HCl **1a** under the standard conditions. Both transformations successfully provided the expected fused hybrids **7a** and **7b**. In a final venture to establish the generality of this strategy, benzene-1,2-diamine was also used to prepare **8a** and **8b** which were readily for further transformation to obtain more complex heteropolycycles **9a** and **9b** with potential drug-likeness (Scheme 6b).

Conclusions

In conclusion, we have fully explored the synthetic application of our recently reported heterocyclic iodoniums (HCIs). These unique iodoniums may gain more attention to build complex



polycyclic heteroarenes which are widely present in naturally occurring products and pharmaceuticals. All the transformations with HCl under went a cyclization to build structurally diverse indole-fused, thiophene-fused, and triphenylene-fused heterocycles. Our current thorough investigation of HCl highlights their value as versatile building blocks in synthetic chemistry, which may provide novel structures for drug development. These particular heterocycles are currently under our anticancer drug screening.

Experimental

The ^1H and ^{13}C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance spectrometer 400 at 400 MHz and 100 MHz, respectively. Chemical shifts are given in ppm (δ) referenced to CDCl_3 with 7.26 for ^1H and 77.10 for ^{13}C , and to d_6 -DMSO with 2.50 for ^1H and 39.5 for ^{13}C . In the case of multiplet, signals are reported as intervals and abbreviated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Coupling constants are expressed in hertz. High-resolution mass spectra (HRMS) were recorded on a BRUKER VPEXII spectrometer with ESI mode unless otherwise stated. Melting point was measured by BUCHI Melting Point B-540. The progress of the reactions was monitored by thin-layer chromatography on a glass plate coated with silica gel with fluorescent indicator (GF254). Column chromatography was performed on silica gel (200–300 mesh).

General procedure A for the synthesis of 3a–4k

The synthesis of 10-(4-methoxyphenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (3a) is exemplified. To a stirred solution of iodonium 1a (0.1 mmol) in *i*-PrOH (0.9 mL), was added ethylene glycol (0.1 mL), *p*-anisidine (2.5 equiv.), Na_2CO_3 (3 equiv.), and $\text{Cu}(\text{OAc})_2$ (0.1 equiv.). The reaction proceeded at reflux for 16 h under argon atmosphere before *i*-PrOH was removed by a rotary evaporation. The remained mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 15/1–5/1) to provide 3a as a white solid (29 mg, 84% yield), mp 199.1–200.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.74–7.68 (m, 2H), 7.51–7.45 (m, 1H), 7.44–7.37 (m, 3H), 7.32 (dd, J = 13.2, 7.9 Hz, 2H), 7.11–7.04 (m, 2H), 3.91 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.2, 159.3, 155.5, 146.0, 139.4, 132.8, 130.0, 129.1, 128.6, 126.4, 124.6, 124.0, 121.1, 120.9, 120.0, 118.1, 115.6, 114.3, 111.6, 55.6 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{NO}_3$ [$\text{M} + \text{H}$] $^+$: 342.1125, found: 342.1112.

10-(4-Methoxyphenyl)-8-methylchromeno[3,2-*b*]indol-11(10*H*)-one (3b). 3b (27 mg, 77% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 195.6–196.3 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.36 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 2.2 Hz, 2H), 7.40 (dd, J = 10.9, 5.9 Hz, 3H), 7.14 (d, J = 8.3 Hz, 1H), 7.11–7.04 (m, 3H), 3.91 (s, 3H), 2.48 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 168.9, 159.3, 155.5, 146.3, 140.0, 139.5, 132.6, 130.2, 129.2, 126.4, 124.7, 123.9, 123.2, 120.7,

119.7, 118.0, 114.3, 113.5, 111.1, 55.7, 22.5 ppm. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{18}\text{NO}_3$ [$\text{M} + \text{H}$] $^+$: 356.1281, found: 356.1284.

8-Chloro-10-(4-methoxyphenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (3c). 3c (24 mg, 74% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 215.1–216.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.34 (d, J = 7.8 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.75–7.64 (m, 2H), 7.41 (dd, J = 11.2, 8.1 Hz, 3H), 7.30 (s, 1H), 7.27 (d, J = 7.0 Hz, 1H), 7.08 (d, J = 8.7 Hz, 2H), 3.91 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 159.6, 155.6, 145.6, 139.6, 134.8, 133.1, 129.5, 129.0, 126.4, 124.5, 124.3, 122.2, 121.4, 121.1, 118.1, 114.5, 114.2, 111.6, 55.7 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{ClNO}_3$ [$\text{M} + \text{H}$] $^+$: 376.0735, found: 376.0742.

8-Fluoro-10-(4-methoxyphenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (3d). 3d (26 mg, 73% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 169.3–170.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.35 (d, J = 7.5 Hz, 1H), 8.02 (dd, J = 8.8, 5.3 Hz, 1H), 7.69 (dd, J = 12.3, 4.9 Hz, 2H), 7.41 (t, J = 7.8 Hz, 3H), 7.05 (dd, J = 14.9, 5.4 Hz, 3H), 6.97 (dd, J = 9.7, 1.8 Hz, 1H), 3.91 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 168.7, 165.0, 162.6, 159.6, 155.5, 145.9, 140.1, 140.0, 132.9, 129.7, 128.9, 126.5, 124.5, 124.2, 121.7, 121.6, 121.5, 118.1, 114.5, 112.4, 111.0, 110.8, 98.0, 97.7, 55.7 ppm. ^{19}F NMR (376 MHz, CDCl_3) δ –109.8, –109.8, –109.8, –109.8, –109.8, –109.9 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{FNO}_3$ [$\text{M} + \text{H}$] $^+$: 360.1030, found: 360.1014.

7-Fluoro-10-(4-methoxyphenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (3e). 3e (20 mg, 56% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 208.9–209.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.40–8.30 (m, 2H), 7.53–7.47 (m, 2H), 7.46–7.41 (m, 2H), 7.40–7.35 (m, 2H), 7.32 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 8.9 Hz, 2H), 3.92 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 159.7, 155.0, 151.2, 142.5, 129.5, 129.2, 127.7, 124.6, 123.6, 122.7, 122.4, 122.3, 121.8, 121.6, 118.8, 117.3, 114.5, 112.5, 55.6 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{FNO}_3$ [$\text{M} + \text{H}$] $^+$: 360.1030, found: 360.1036.

10-(4-Methoxyphenyl)thiochromeno[3,2-*b*]indol-11(10*H*)-one (3f). 3f (19 mg, 53% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 224.9–225.5 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.64 (d, J = 8.1 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.65–7.56 (m, 1H), 7.48 (dd, J = 18.4, 7.5 Hz, 2H), 7.35 (d, J = 8.8 Hz, 2H), 7.33–7.29 (m, 1H), 7.25 (d, J = 9.7 Hz, 1H), 7.08 (d, J = 8.8 Hz, 2H), 3.92 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 172.3, 159.4, 141.2, 135.9, 132.8, 131.4, 130.8, 129.2, 129.2, 128.6, 128.2, 126.9, 126.2, 123.2, 121.2, 120.6, 120.3, 114.3, 112.2, 55.6 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{NO}_2\text{S}$ [$\text{M} + \text{H}$] $^+$: 358.0896, found: 358.0889.

7-(4-Methoxyphenyl)-7*H*-indolo[2,3-*c*]quinolone (3g). 3g (25 mg, 77% yield) was generated following a procedure for the synthesis of 3a as a white solid, mp 130.4–131.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.08 (s, 1H), 8.77 (d, J = 8.2 Hz, 1H), 8.64 (d, J = 8.0 Hz, 1H), 8.31 (d, J = 8.3 Hz, 1H), 7.76 (t, J = 7.5 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.59–7.54 (m, 1H), 7.48 (dd, J = 18.5, 7.9 Hz, 4H), 7.17 (d, J = 8.7 Hz, 2H), 3.95 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 159.7, 143.5, 141.4, 137.4, 134.1, 130.5, 129.1, 128.9, 127.4, 127.2, 125.9, 124.7, 123.5, 123.4, 122.2, 121.4, 121.3, 115.5, 111.3, 55.8 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$: 325.1335, found: 325.1330.



7-(4-Methoxyphenyl)-9-methyl-7H-indolo[2,3-c]quinolone (3h). **3h** (25 mg, 74% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 177.9–179.1 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1H), 8.71 (d, *J* = 8.1 Hz, 1H), 8.47 (d, *J* = 8.7 Hz, 1H), 8.28 (d, *J* = 8.2 Hz, 1H), 7.72 (t, *J* = 7.4 Hz, 1H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.47 (d, *J* = 8.8 Hz, 2H), 7.26 (t, *J* = 7.6 Hz, 2H), 7.15 (d, *J* = 8.8 Hz, 2H), 3.93 (s, 3H), 2.53 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 159.6, 143.5, 141.9, 137.8, 137.3, 134.1, 130.5, 129.2, 128.9, 127.1, 125.8, 124.6, 123.5, 123.1, 123.1, 121.5, 120.0, 115.4, 111.1, 55.8, 22.3 ppm. HRMS (ESI) *m/z* calcd for C₂₃H₁₉N₂O [M + H]⁺: 339.1492, found: 339.1487.

9-Chloro-7-(4-methoxyphenyl)-7H-indolo[2,3-c]quinolone (3i). **3i** (18 mg, 51% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 204.7–205.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1H), 8.65 (d, *J* = 8.0 Hz, 1H), 8.48 (d, *J* = 8.5 Hz, 1H), 8.30 (d, *J* = 8.1 Hz, 1H), 7.74 (t, *J* = 7.4 Hz, 1H), 7.68 (t, *J* = 7.4 Hz, 1H), 7.46 (d, *J* = 8.5 Hz, 3H), 7.40 (d, *J* = 8.6 Hz, 1H), 7.17 (d, *J* = 8.7 Hz, 2H), 3.95 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 160.0, 143.3, 141.9, 137.1, 134.4, 133.4, 130.4, 128.8, 128.4, 127.6, 126.4, 124.3, 123.3, 122.1, 121.2, 120.7, 115.6, 111.3, 55.8 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₆ClN₂O [M + H]⁺: 359.0946, found: 359.0940.

2-Fluoro-7-(4-methoxyphenyl)-7H-indolo[2,3-c]quinolone (3j). **3j** (21 mg, 62% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 161.1–161.8 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.01 (s, 1H), 8.52 (d, *J* = 7.9 Hz, 1H), 8.28 (ddd, *J* = 15.1, 9.5, 4.2 Hz, 2H), 7.60–7.53 (m, 1H), 7.52–7.45 (m, 4H), 7.41 (td, *J* = 8.8, 2.7 Hz, 1H), 7.17 (d, *J* = 8.8 Hz, 2H), 3.95 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 160.3, 159.8, 141.3, 140.4, 136.7, 134.2, 132.8, 132.7, 128.9, 128.8, 127.3, 125.4, 125.3, 122.9, 122.0, 121.6, 121.0, 115.6, 115.5, 115.3, 111.4, 107.6, 107.4, 55.8 ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ −112.2, −112.2, −112.2, −112.3 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₆FN₂O [M + H]⁺: 343.1241, found: 343.1229.

11-(4-Methoxyphenyl)-11H-indolo[3,2-c]isoquinoline (3k). **3k** (25 mg, 78% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 185.8–186.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.17 (s, 1H), 8.49 (d, *J* = 7.4 Hz, 1H), 8.12 (d, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 7.3 Hz, 1H), 7.50–7.39 (m, 6H), 7.21 (d, *J* = 8.0 Hz, 1H), 7.16 (d, *J* = 8.7 Hz, 2H), 3.97 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 160.2, 146.2, 142.0, 135.1, 131.6, 130.2, 129.4, 129.1, 128.4, 127.7, 126.1, 125.7, 124.5, 122.9, 121.2, 121.0, 119.9, 115.4, 110.4, 55.8 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₇N₂O [M + H]⁺: 325.1335, found: 325.1327.

11-(4-Methoxyphenyl)-9-methyl-11H-indolo[3,2-c]isoquinoline (3l). **3l** (25 mg, 74% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 173.8–175.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.15 (s, 1H), 8.37 (d, *J* = 8.0 Hz, 1H), 8.11 (d, *J* = 8.1 Hz, 1H), 7.54–7.49 (m, 1H), 7.48–7.42 (m, 3H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.26–7.22 (m, 1H), 7.17 (d, *J* = 8.8 Hz, 2H), 6.99 (s, 1H), 3.98 (s, 3H), 2.50 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 160.1, 145.8, 142.5, 136.6, 135.1, 131.7, 130.3, 129.4, 129.2, 128.2, 127.5, 125.4, 124.6, 122.8, 121.1, 120.6, 119.7, 115.4, 110.4, 55.8,

22.3 ppm. HRMS (ESI) *m/z* calcd for C₂₃H₁₉N₂O [M + H]⁺: 339.1492, found: 339.1489.

7-(4-Methoxyphenyl)chromeno[3,4-b]indol-6(7H)-one (3m). **3m** (26 mg, 75% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 231.1–232.5 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.76–7.64 (m, 3H), 7.44–7.35 (m, 3H), 7.29–7.18 (m, 3H), 7.07 (d, *J* = 8.9 Hz, 2H), 3.91 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 159.5, 155.6, 145.5, 136.0, 133.1, 129.8, 129.1, 126.4, 124.5, 124.1, 122.1, 118.1, 117.8, 117.5, 115.5, 115.4, 114.4, 113.1, 113.0, 104.7, 104.4, 55.7 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₆NO₃ [M + H]⁺: 342.1125, found: 342.1124.

4-(4-Methoxyphenyl)-4H-thieno[3,2-b]indole (3n). **3n** (16 mg, 57% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 125.1–126.9 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 7.4 Hz, 1H), 7.48 (t, *J* = 8.6 Hz, 3H), 7.36 (d, *J* = 5.2 Hz, 1H), 7.29–7.19 (m, 2H), 7.08 (d, *J* = 8.8 Hz, 2H), 7.04 (d, *J* = 5.2 Hz, 1H), 3.91 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 158.5, 145.6, 141.8, 131.8, 126.9, 126.8, 124.4, 123.0, 122.2, 120.1, 119.0, 117.4, 115.0, 114.7, 111.4, 111.0, 55.7 ppm. HRMS (ESI) *m/z* calcd for C₁₇H₁₄NOS [M + H]⁺: 280.0791, found: 280.0787.

10-Phenylchromeno[3,2-b]indol-11(10H)-one (4a). **4a** (24 mg, 79% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 190.7–191.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, *J* = 7.8 Hz, 1H), 8.10 (d, *J* = 8.1 Hz, 1H), 7.72 (d, *J* = 3.0 Hz, 2H), 7.60–7.54 (m, 2H), 7.53–7.46 (m, 4H), 7.45–7.40 (m, 1H), 7.38 (d, *J* = 8.5 Hz, 1H), 7.33 (t, *J* = 7.5 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 155.5, 146.3, 139.0, 137.1, 132.8, 129.0, 128.7, 128.1, 128.0, 126.4, 124.5, 124.0, 121.2, 120.6, 120.0, 118.1, 115.7, 111.5 ppm. HRMS (ESI) *m/z* calcd for C₂₁H₁₄NO₂ [M + H]⁺: 312.1019, found: 312.1017.

10-(p-Tolyl)chromeno[3,2-b]indol-11(10H)-one (4b). **4b** (30 mg, 92% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 205.2–206.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, *J* = 7.9 Hz, 1H), 8.09 (d, *J* = 8.1 Hz, 1H), 7.71 (d, *J* = 3.0 Hz, 2H), 7.51–7.45 (m, 1H), 7.44–7.40 (m, 1H), 7.41–7.34 (m, 5H), 7.31 (t, *J* = 7.5 Hz, 1H), 2.48 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 169.1, 155.5, 146.1, 139.1, 138.0, 134.5, 132.8, 129.7, 128.6, 127.7, 126.4, 124.5, 124.0, 121.1, 120.7, 120.0, 118.0, 115.6, 111.6, 21.4 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₆NO₂ [M + H]⁺: 326.1176, found: 326.1171.

10-(4-Fluorophenyl)chromeno[3,2-b]indol-11(10H)-one (4c). **4c** (24 mg, 74% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 227.5–228.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, *J* = 7.9 Hz, 1H), 8.09 (d, *J* = 8.1 Hz, 1H), 7.72 (t, *J* = 5.8 Hz, 2H), 7.57–7.40 (m, 4H), 7.38–7.30 (m, 2H), 7.26 (dd, *J* = 11.0, 6.0 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 169.2, 163.4, 161.0, 155.6, 146.3, 139.2, 133.2, 133.0, 129.8, 129.7, 128.9, 126.3, 124.5, 124.2, 121.4, 120.7, 120.2, 118.2, 116.1, 115.9, 115.8, 111.4 ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ −113.4, −113.5, −113.5, −113.5, −113.5, −113.5, −113.5 ppm. HRMS (ESI) *m/z* calcd for C₂₁H₁₃FO₂ [M + H]⁺: 330.0925, found: 330.0934.

10-(4-Chlorophenyl)chromeno[3,2-b]indol-11(10H)-one (4d). **4d** (23 mg, 65% yield) was generated following a procedure for



the synthesis of **3a** as a white solid, mp 265.6–266.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.40–8.30 (m, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.72 (dd, J = 5.7, 1.4 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 7.51–7.48 (m, 1H), 7.47–7.40 (m, 3H), 7.39–7.31 (m, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.2, 155.6, 146.5, 139.0, 135.7, 133.9, 133.1, 129.3, 129.0, 126.4, 124.5, 124.3, 121.6, 120.6, 120.2, 118.2, 116.0, 111.4 ppm. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{13}\text{ClNO}_2$ $[\text{M} + \text{H}]^+$: 346.0629, found: 346.0621.

10-(4-Bromophenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (4e). **4e** (22 mg, 65% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 283.5–284.7 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.36 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.78–7.64 (m, 4H), 7.50 (t, J = 7.7 Hz, 1H), 7.46–7.29 (m, 5H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.2, 155.6, 146.5, 138.9, 136.2, 133.1, 132.3, 129.6, 129.1, 126.4, 124.5, 124.3, 121.9, 121.6, 120.5, 120.3, 118.2, 116.1, 111.4 ppm. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{13}\text{BrNO}_2$ $[\text{M} + \text{H}]^+$: 390.0124, found: 390.0127.

10-(4-Iodophenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (4f). **4f** (24 mg, 54% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 241.1–242.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.36 (d, J = 7.7 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.72 (t, J = 6.1 Hz, 2H), 7.54–7.48 (m, 1H), 7.46–7.41 (m, 1H), 7.35 (dd, J = 17.3, 8.1 Hz, 2H), 7.27 (d, J = 6.7 Hz, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 155.5, 146.6, 138.8, 138.2, 136.9, 133.0, 129.8, 129.0, 126.4, 124.5, 124.3, 121.6, 120.5, 120.3, 118.2, 116.1, 111.4, 93.3 ppm. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{13}\text{INO}_2$ $[\text{M} + \text{H}]^+$: 437.9986, found: 437.9986.

10-(4-(Trifluoromethyl)phenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (4g). **4g** (20 mg, 52% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 247.8–248.5 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.40–8.33 (m, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.74 (dt, J = 8.0, 4.0 Hz, 2H), 7.65 (d, J = 8.3 Hz, 2H), 7.52 (dd, J = 11.4, 4.1 Hz, 1H), 7.47–7.43 (m, 1H), 7.43–7.34 (m, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.2, 155.5, 147.0, 140.2, 138.8, 133.2, 129.3, 128.3, 126.4, 126.2, 124.4, 121.9, 120.4, 118.2, 116.3, 111.3 ppm. ^{19}F NMR (376 MHz, CDCl_3) δ –62.4 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{13}\text{F}_3\text{NO}_2$ $[\text{M} + \text{H}]^+$: 380.0893, found: 380.0908.

Methyl 4-(11-oxochromeno[3,2-*b*]indol-10(11*H*)-yl)benzoate (4h). **4h** (15 mg, 41% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 232.4–233.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.37 (d, J = 7.5 Hz, 1H), 8.24 (d, J = 8.5 Hz, 2H), 8.11 (d, J = 8.0 Hz, 1H), 7.78–7.70 (m, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.55–7.49 (m, 1H), 7.48–7.40 (m, 2H), 7.36 (t, J = 7.5 Hz, 1H), 3.98 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.1, 166.6, 155.6, 147.0, 141.2, 138.8, 133.1, 130.5, 129.5, 129.2, 127.8, 126.5, 124.5, 124.3, 121.8, 120.5, 120.3, 118.2, 116.3, 111.5, 52.4 ppm. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{NO}_4$ $[\text{M} + \text{H}]^+$: 370.1074, found: 370.1074.

Methyl 2-(11-oxochromeno[3,2-*b*]indol-10(11*H*)-yl)benzoate (4i). **4i** (12 mg, 32% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 219.9–221.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.33 (d, J = 7.9 Hz, 1H), 8.20 (dd, J = 7.8, 1.4 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.78–7.66 (m, 3H), 7.61 (td, J = 7.7, 1.1 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.50–7.43 (m, 1H), 7.43–7.37 (m, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.15 (d, J =

8.5 Hz, 1H), 3.46 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 165.6, 155.7, 146.0, 139.2, 137.3, 132.9, 132.8, 131.6, 130.5, 129.5, 128.8, 128.7, 126.3, 124.4, 124.0, 121.5, 121.2, 120.1, 118.2, 115.8, 111.1, 52.2 ppm. HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{NO}_4$ $[\text{M} + \text{H}]^+$: 370.1074, found: 370.1078.

10-(Pyridin-2-yl)chromeno[3,2-*b*]indol-11(10*H*)-one (4j). **4j** (11 mg, 34% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 191.3–192.5 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.67 (s, 1H), 8.39 (d, J = 7.9 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 7.93 (t, J = 7.2 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.72 (s, 2H), 7.54 (t, J = 7.6 Hz, 2H), 7.45 (dd, J = 14.0, 6.4 Hz, 1H), 7.42–7.33 (m, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.0, 155.5, 150.6, 148.4, 147.7, 138.8, 137.9, 133.0, 129.5, 126.5, 124.6, 124.3, 122.6, 122.5, 122.1, 120.1, 120.0, 118.2, 116.7, 113.0 ppm. HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{13}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: 313.0972, found: 313.0963.

10-(Quinolin-8-yl)chromeno[3,2-*b*]indol-11(10*H*)-one (4k). **4k** (24 mg, 67% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 213.5–214.5 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.76 (d, J = 3.0 Hz, 1H), 8.28 (dd, J = 18.7, 7.9 Hz, 2H), 8.15 (d, J = 8.0 Hz, 1H), 8.03 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 7.1 Hz, 1H), 7.73 (dd, J = 15.9, 8.4 Hz, 3H), 7.48–7.30 (m, 4H), 7.08 (d, J = 8.4 Hz, 1H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.3, 155.8, 150.9, 146.2, 145.2, 139.9, 136.7, 135.1, 132.7, 129.8, 129.3, 129.0, 128.5, 126.3, 126.3, 124.7, 123.9, 122.6, 121.9, 121.2, 120.2, 118.2, 116.2, 111.8 ppm. HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{15}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: 363.1128, found: 363.1113.

General procedure B for the synthesis of 4l–4o

The synthesis of 10-(2-(pyridin-2-yl)ethyl)chromeno[3,2-*b*]indol-11(10*H*)-one (**4l**) is exemplified. To a stirred solution of iodonium **1a** (0.1 mmol) in *i*-PrOH (0.9 mL), was added ethylene glycol (0.1 mL), 2-(pyridin-2-yl)ethan-1-amine (2.5 equiv.), Na_2CO_3 (3 equiv.), $\text{Cu}(\text{OAc})_2$ (0.1 equiv.), and CuI (0.1 equiv.). The reaction proceeded at reflux for 16 h under argon atmosphere before *i*-PrOH was removed by a rotary evaporation. The remained mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 15/1–5/1) to provide **4l** as a white solid (23 mg, 68% yield), mp 139.7–140.8 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.55 (d, J = 4.3 Hz, 1H), 8.45 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.75–7.59 (m, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.34 (dd, J = 20.0, 7.8 Hz, 2H), 7.17 (t, J = 7.4 Hz, 1H), 7.06 (t, J = 8.4 Hz, 2H), 5.08 (t, J = 7.3 Hz, 2H), 3.37 (t, J = 7.2 Hz, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 170.1, 158.8, 155.6, 149.5, 145.2, 138.0, 136.5, 132.7, 128.1, 126.1, 124.4, 123.9, 123.9, 121.7, 120.2, 120.0, 119.9, 118.1, 114.7, 110.5, 45.0, 39.9 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$: 341.1285, found: 341.1278.

10-Butylchromeno[3,2-*b*]indol-11(10*H*)-one (4m). **4m** (20 mg, 68% yield) was generated following a procedure for the synthesis of **4l** as a white solid, mp 87.4–88.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.45 (dd, J = 8.0, 1.3 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.74–7.61 (m, 2H), 7.57–7.46 (m, 2H), 7.45–7.40 (m, 1H), 7.25 (ddd, J = 7.9, 5.3, 1.1 Hz, 1H), 4.76 (t, J = 7.3 Hz, 2H), 1.94–



1.76 (m, 2H), 1.41 (dd, $J = 15.3, 7.5$ Hz, 2H), 0.95 (t, $J = 7.4$ Hz, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 155.6, 145.0, 137.9, 132.7, 128.1, 126.3, 124.5, 123.9, 120.4, 120.2, 118.2, 115.0, 110.6, 44.8, 33.1, 20.2, 14.0 ppm. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_2$ $[\text{M} + \text{H}]^+$: 292.1332, found: 292.1337.

10-Cyclopropylchromeno[3,2-*b*]indol-11(10*H*)-one (4n). 4n (23 mg, 82% yield) was generated following a procedure for the synthesis of **4l** as a white solid, mp 167.9–168.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.46 (dd, $J = 8.0, 1.4$ Hz, 1H), 8.03–7.98 (m, 1H), 7.73 (d, $J = 8.5$ Hz, 1H), 7.71–7.63 (m, 2H), 7.52 (ddd, $J = 8.4, 5.4, 1.2$ Hz, 1H), 7.43 (ddd, $J = 8.1, 6.8, 1.4$ Hz, 1H), 7.30–7.23 (m, 1H), 3.63–3.54 (m, 1H), 1.40–1.33 (m, 2H), 1.17 (qd, $J = 5.6, 4.5$ Hz, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 169.5, 155.4, 145.5, 139.1, 132.7, 128.1, 126.4, 124.8, 124.0, 121.6, 120.6, 120.1, 118.0, 115.2, 112.3, 26.6, 9.5 ppm. HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{NO}_2$ $[\text{M} + \text{H}]^+$: 276.1019, found: 276.1011.

10-(4-Hydroxybutyl)chromeno[3,2-*b*]indol-11(10*H*)-one (4o). 4o (27 mg, 88% yield) was generated following a procedure for the synthesis of **4l** as a white solid, mp 110.7–111.3 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.44 (d, $J = 7.8$ Hz, 1H), 8.03 (d, $J = 8.1$ Hz, 1H), 7.76–7.62 (m, 2H), 7.57–7.46 (m, 2H), 7.44 (t, $J = 7.2$ Hz, 1H), 7.30–7.18 (m, 1H), 4.81–4.73 (m, 2H), 3.75 (t, $J = 6.2$ Hz, 2H), 2.01 (dt, $J = 14.8, 7.4$ Hz, 2H), 1.74–1.55 (m, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 155.5, 145.2, 137.9, 132.8, 128.4, 126.2, 124.2, 123.9, 120.3, 120.2, 118.1, 114.9, 110.4, 62.1, 44.2, 29.4, 27.2 ppm. HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_3$ $[\text{M} + \text{H}]^+$: 308.1281, found: 308.1278.

Procedure for the synthesis of triethylammonium benzyl-carbamodithioate (M1). To a solution of benzylamine (1.11 g, 10.38 mmol, 1.05 equiv.) and Et_3N (1.0 g, 9.88 mmol, 1 equiv.) in CH_2Cl_2 (25 mL), CS_2 (0.83 g, 10.87 mmol, 1.1 equiv.) was dropped slowly. The solution was stirred at room temperature for 3 h, concentrated by a rotary evaporator, and finally dried by a high vacuum to give **M1** (2.75 g, 98% yield) as a white solid.

The reaction procedure of heterocyclic iodoniums and M1 to provide benzothiophene-fused heterocycles 5. Syntheses of 8-methyl-11*H*-benzo[4,5]thieno[3,2-*b*]chromen-11-one (**5a**) is exemplified. To a stirred solution of iodonium **1b** (0.1 mmol) in MeCN (2.0 mL), was added **M1** (2 equiv.) and CuSO_4 (0.1 equiv.). The reaction proceeded at 70 °C for 6 h under argon atmosphere before MeCN was removed by a rotary evaporation. The remained mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 20/1–5/1) to provide **5a** as a white solid (22 mg, 85% yield), mp 191.2–192.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.39 (dd, $J = 8.0, 1.5$ Hz, 1H), 8.07 (d, $J = 8.2$ Hz, 1H), 7.79–7.72 (m, 1H), 7.72–7.64 (m, 2H), 7.48 (dd, $J = 11.0, 3.9$ Hz, 1H), 7.35 (d, $J = 8.2$ Hz, 1H), 2.54 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 173.3, 156.0, 153.9, 140.4, 140.2, 133.7, 127.0, 126.0, 124.9, 123.6, 122.7, 122.1, 119.9, 118.1, 22.1 ppm. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{11}\text{O}_2\text{S}[\text{M} + \text{H}]^+$: 267.0474, found: 267.0481.

Benzo[4,5]thieno[2,3-*c*]quinolone (5b). 5b (18 mg, 76% yield) was generated following a procedure for the synthesis of **5a** as a white solid, mp 129.7–131.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.40 (s, 1H), 8.98–8.93 (m, 1H), 8.91 (dd, $J = 5.8, 2.9$ Hz, 1H),

8.49–8.38 (m, 1H), 8.10 (dd, $J = 5.5, 3.6$ Hz, 1H), 7.82 (dd, $J = 5.7, 3.9$ Hz, 2H), 7.75–7.63 (m, 2H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 145.5, 145.4, 141.5, 135.6, 135.2, 133.4, 130.7, 127.9, 127.7, 126.1, 125.5, 123.9, 123.0 ppm. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{10}\text{NS}[\text{M} + \text{H}]^+$: 236.0528, found: 236.0520.

9-Methylbenzo[4,5]thieno[3,2-*c*]isoquinoline (5c). 5c (15 mg, 59% yield) was generated following a procedure for the synthesis of **5a** as a white solid, mp 108.8–110.3 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.31 (s, 1H), 8.53 (d, $J = 8.1$ Hz, 1H), 8.16 (d, $J = 8.1$ Hz, 1H), 8.09 (d, $J = 8.3$ Hz, 1H), 7.85 (t, $J = 7.6$ Hz, 1H), 7.76 (s, 1H), 7.69 (t, $J = 7.6$ Hz, 1H), 7.42 (d, $J = 8.2$ Hz, 1H), 2.57 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 150.2, 138.7, 137.9, 133.5, 132.0, 131.2, 129.5, 129.1, 127.9, 127.3, 127.2, 126.9, 126.8, 123.7, 123.6, 123.0, 122.8, 122.7, 122.4, 22.0 ppm. HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{12}\text{NS}[\text{M} + \text{H}]^+$: 250.0685, found: 250.0677.

6*H*-Benzo[4,5]thieno[2,3-*c*]chromen-6-one (5d). 5d (21 mg, 84% yield) was generated following a procedure for the synthesis of **5a** as a white solid, mp 205.0–206.8 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.69–8.59 (m, 1H), 8.50 (d, $J = 8.0$ Hz, 1H), 8.06–7.97 (m, 1H), 7.67–7.60 (m, 2H), 7.56 (q, $J = 8.3$ Hz, 2H), 7.46 (t, $J = 7.2$ Hz, 1H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 158.0, 152.6, 143.6, 138.6, 134.9, 130.0, 128.4, 126.0, 125.6, 124.8, 124.0, 123.5, 118.3, 118.0 ppm. HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_9\text{O}_2\text{S}[\text{M} + \text{H}]^+$: 253.0318, found: 253.0313.

General procedure for synthesis of 6

The synthesis of 6-methyl-14*H*-dibenzo[*a,c*]xanthen-14-one (**6a**) is exemplified. To a stirred solution of 2-chlorobenzoic acid (0.1 mmol) in 1-methyl-2-pyrrolidinone (1.5 mL), was added heterocyclic iodonium (1.2 equiv.), $\text{Pd}(\text{OAc})_2$ (0.1 equiv.), and K_2CO_3 (2.2 equiv.). The reaction mixture was sealed in a tube. The reaction proceeded at 140 °C for 16 h before it was cooled to rt. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 20/1–5/1) to provide **6a** as a white solid (20 mg, 63% yield), mp 207.5–209.2 °C. ^1H NMR (400 MHz, CDCl_3) δ 10.08 (dd, $J = 8.4, 0.9$ Hz, 1H), 8.49 (d, $J = 8.1$ Hz, 1H), 8.39 (dd, $J = 8.0, 1.8$ Hz, 2H), 8.26 (s, 1H), 7.69 (dddd, $J = 12.7, 8.3, 7.1, 1.4$ Hz, 2H), 7.62–7.56 (m, 1H), 7.54 (d, $J = 8.2$ Hz, 1H), 7.45–7.40 (m, 1H), 7.38 (d, $J = 8.3$ Hz, 1H), 2.55 (s, 3H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 178.2, 155.3, 154.3, 141.0, 133.9, 133.6, 129.2, 128.9, 128.4, 127.7, 127.2, 126.7, 126.5, 124.6, 124.0, 123.9, 122.7, 122.3, 121.6, 117.5, 112.0, 22.4 ppm. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{15}\text{O}_2[\text{M} + \text{H}]^+$: 311.1067, found: 311.1062.

14*H*-Dibenzo[*a,c*]thioxanthen-14-one (6b). 6b (18 mg, 58% yield) was generated following a procedure for the synthesis of **6a** as a white solid, mp 198.6–199.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.59–9.43 (m, 1H), 8.67 (d, $J = 8.3$ Hz, 1H), 8.64–8.59 (m, 1H), 8.53 (d, $J = 7.9$ Hz, 1H), 8.46 (d, $J = 8.2$ Hz, 1H), 7.77 (t, $J = 7.6$ Hz, 1H), 7.73–7.59 (m, 5H), 7.54 (t, $J = 7.5$ Hz, 1H) ppm. ^{13}C NMR (100 MHz, CDCl_3) δ 182.9, 139.2, 134.1, 132.3, 131.7, 131.6, 130.1, 129.9, 129.5, 129.4, 128.0, 127.7, 127.5, 127.4,



127.3, 127.2, 125.6, 124.9, 124.7, 123.5, 122.6 ppm. HRMS (ESI) m/z calcd for $C_{21}H_{13}OS [M + H]^+$: 313.0682, found: 313.0671.

9-Fluorodibenzo[*i,k*]phenanthridine (6c). **6c** (17 mg, 57% yield) was generated following a procedure for the synthesis of **6a** as a white solid, mp 151.9–152.5 °C. 1H NMR (400 MHz, $CDCl_3$) δ 10.04 (s, 1H), 8.88 (d, J = 8.2 Hz, 1H), 8.82–8.64 (m, 3H), 8.54 (dd, J = 11.2, 2.3 Hz, 1H), 8.31 (dd, J = 9.0, 6.0 Hz, 1H), 7.86–7.69 (m, 4H), 7.61–7.46 (m, 1H) ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.6, 160.2, 146.2, 143.7, 132.6, 132.0, 131.9, 130.5, 129.1, 129.0, 128.5, 128.3, 128.1, 127.6, 127.2, 124.0, 123.5, 123.2, 122.6, 118.4, 118.1, 112.1, 111.8 ppm. ^{19}F NMR (376 MHz, $CDCl_3$) δ –112.6 ppm. HRMS (ESI) m/z calcd for $C_{21}H_{13}FN [M + H]^+$: 298.1027, found: 298.1024.

General procedure for synthesis of 7

10-(2-(1*H*-Indol-3-yl)ethyl)chromeno[3,2-*b*]indol-11(10*H*)-one (7a). **7a** (48 mg, 63% yield) was generated following a procedure for the synthesis of **4l** as a white solid, mp 157.5–158.6 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.55–8.45 (m, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.97 (s, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.76–7.66 (m, 2H), 7.50–7.44 (m, 1H), 7.43–7.38 (m, 1H), 7.35 (d, J = 7.0 Hz, 1H), 7.29 (d, J = 8.6 Hz, 1H), 7.25–7.16 (m, 3H), 6.97 (d, J = 2.0 Hz, 1H), 5.09–4.96 (m, 2H), 3.43–3.25 (m, 2H) ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.3, 155.6, 145.2, 138.1, 136.4, 132.8, 128.1, 127.6, 126.3, 124.4, 124.0, 122.5, 122.2, 120.2, 120.1, 119.7, 118.9, 118.2, 114.9, 112.8, 111.3, 110.4, 100.1, 45.8, 27.1 ppm. HRMS (ESI) m/z calcd for $C_{25}H_{19}N_2O_2 [M + H]^+$: 379.1441, found: 379.1442.

10-((3*R*)-10,13-Dimethyl-17-oxohexadecahydro-1*H*-cyclopenta[*a*]phenanthren-3-yl)chromeno[3,2-*b*]indol-11(10*H*)-one (7b). **7b** (57 mg, 56% yield) was generated following a procedure for the synthesis of **4l** as a white solid, mp 167.5–168.6 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (d, J = 7.6 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 7.70 (dd, J = 14.6, 7.1 Hz, 2H), 7.61 (d, J = 8.2 Hz, 1H), 7.51 (s, 1H), 7.45 (s, 1H), 7.27 (d, J = 9.2 Hz, 1H), 5.99 (d, J = 6.3 Hz, 1H), 2.76–2.64 (m, 1H), 2.48 (dd, J = 19.2, 8.4 Hz, 1H), 2.27 (s, 1H), 2.10 (dd, J = 19.3, 9.6 Hz, 1H), 2.05–1.91 (m, 3H), 1.84 (t, J = 14.4 Hz, 2H), 1.71 (s, 5H), 1.51 (dt, J = 26.0, 13.5 Hz, 5H), 1.30 (d, J = 8.6 Hz, 4H), 1.12 (s, 3H), 1.07 (s, 1H), 0.93 (s, 3H), 0.89 (d, J = 11.4 Hz, 2H) ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 170.2, 155.2, 145.5, 136.9, 132.8, 127.8, 126.4, 124.5, 123.9, 120.5, 120.3, 120.0, 118.0, 115.7, 112.5, 56.3, 51.6, 50.4, 48.1, 39.6, 36.9, 36.0, 35.6, 34.4, 33.0, 31.9, 30.6, 28.4, 26.3, 21.9, 20.8, 17.4, 14.0 ppm. ^{13}C NMR (100 MHz, dept 90, $CDCl_3$) δ 132.7, 127.7, 126.3, 123.8, 120.4, 120.0, 117.9, 112.4, 56.2, 51.4, 50.3, 39.5, 35.5 ppm. ^{13}C NMR (100 MHz, dept 135, $CDCl_3$) δ 132.7, 127.7, 126.3, 123.8, 120.4, 119.9, 117.9, 112.4, 56.2, 51.4, 50.3, 39.5, 36.8, 35.9, 35.5, 32.9, 31.8, 30.5, 28.3, 26.2, 21.8, 20.7, 17.3, 13.9 ppm. HRMS (ESI) m/z calcd for $C_{34}H_{38}NO_3 [M + H]^+$: 508.2846, found: 508.2855.

10-(2-Aminophenyl)chromeno[3,2-*b*]indol-11(10*H*)-one (8a). **8a** (43 mg, 66% yield) was generated following a procedure for the synthesis of **3a** as a pink solid, mp 215.5–216.8 °C. 1H NMR (500 MHz, $CDCl_3$) δ 8.33 (d, J = 7.2 Hz, 1H), 8.09 (d, J = 8.0 Hz,

1H), 7.77–7.66 (m, 2H), 7.49 (t, J = 7.6 Hz, 1H), 7.40 (dd, J = 14.6, 6.9 Hz, 1H), 7.34 (dd, J = 9.3, 5.4 Hz, 2H), 7.23 (d, J = 8.5 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 6.8 Hz, 1H), 6.91 (s, 1H), 2.71 (s, 2H). ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 169.3, 155.8, 146.3, 139.0, 133.0, 130.0, 129.6, 128.9, 126.5, 124.6, 124.2, 121.5, 120.1, 119.1, 118.2, 116.9, 115.9, 112.1 ppm. HRMS (ESI) m/z calcd for $C_{21}H_{15}N_2O_2 [M + H]^+$: 327.1128, found: 327.1127.

10-(2-Aminophenyl)-3-methoxychromeno[3,2-*b*]indol-11(10*H*)-one (8b). **8b** (48 mg, 68% yield) was generated following a procedure for the synthesis of **3a** as a white solid, mp 224.2–226.1 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.38 (d, J = 8.8 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.6 Hz, 2H), 7.41 (s, 1H), 7.35 (dd, J = 12.6, 8.3 Hz, 2H), 7.13 (d, J = 8.9 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 4.11 (s, 3H). ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 169.1, 163.7, 157.5, 145.9, 144.2, 138.6, 130.0, 129.6, 128.5, 127.7, 123.5, 121.3, 121.0, 119.8, 118.9, 118.4, 116.7, 115.9, 113.4, 112.0, 100.6, 56.0 ppm. HRMS (ESI) m/z calcd for $C_{22}H_{17}N_2O_3 [M + H]^+$: 357.1234, found: 357.1237.

Procedure for the synthesis of 9a

To a stirred solution of **8a** (40 mg) in dichloromethane (3 mL), was added acetyl chloride (1.2 equiv.) and triethylamine (2.0 equiv.). The reaction proceeded at rt for 4 h before dichloromethane was removed by a rotary evaporation. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 10/1–5/1) to provide *N*-(2-(11-oxochromeno[3,2-*b*]indol-10(11*H*)-yl)phenyl)acetamide (42 mg) as a yellow solid. Then, to this obtained solid was added polyphosphoric acid (0.2 mL) and $POCl_3$ (10 equiv.). The reaction proceeded in a sealed tube at 120 °C for 3 h. The reaction mixture was neutralized with $NaHCO_3$ (Sat.) and extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 10/1–3/1) to provide 6-methyl-15*H*-benzo[2,3][1,4] diazepino [6,7,1-*h,i*]chromeno [3,2-*b*]indol-15-one **9a** as a yellow solid (33 mg, 51% yield over two steps), mp 198.2–199.4 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.47 (dd, J = 8.0, 1.5 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.81–7.74 (m, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 7.3 Hz, 1H), 7.53–7.48 (m, 1H), 7.33 (t, J = 7.8 Hz, 2H), 7.17–7.10 (m, 2H), 6.75–6.65 (m, 1H), 2.60 (s, 3H) ppm. ^{13}C NMR (100 MHz, $CDCl_3$) δ 169.4, 167.1, 155.5, 151.9, 151.0, 139.7, 135.2, 133.5, 129.5, 129.4, 127.5, 126.9, 125.9, 125.8, 124.9, 124.6, 124.4, 123.8, 122.6, 122.2, 119.8, 118.1, 28.5 ppm. HRMS (ESI) m/z calcd for $C_{23}H_{15}N_2O_2 [M + H]^+$: 351.1128, found: 351.1127.

Procedure for the synthesis of 9b

To a stirred solution of **8b** (45 mg) in EtOH (4 mL), was added TsOH· H_2O (0.1 equiv.). The reaction proceeded at a reflux overnight before EtOH was removed by a rotary evaporation. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with H_2O and brine, dried over anhydrous Na_2SO_4 , and evaporated in a *vacuo*. The residue was purified by column chromatography (PE/EtOAc = 10/1–5/1) to



provide 8-methoxy-10-oxa-5,14*b*-diazaindeno [1,2,3-*g,h*]tetraphene **9b** as a yellow solid (41 mg, 95% yield), mp 173.5–174.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.33 (d, *J* = 8.0 Hz, 1H), 8.24 (d, *J* = 8.6 Hz, 1H), 8.02 (dd, *J* = 17.2, 8.0 Hz, 2H), 7.75 (d, *J* = 7.3 Hz, 1H), 7.58 (t, *J* = 7.8 Hz, 1H), 7.44 (t, *J* = 7.5 Hz, 1H), 7.32 (t, *J* = 7.6 Hz, 1H), 7.27–7.21 (m, 1H), 6.92 (d, *J* = 10.1 Hz, 2H), 3.93 (s, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 158.1, 148.0, 139.5, 132.8, 131.2, 130.3, 129.1, 126.3, 125.8, 125.1, 124.6, 121.6, 119.2, 118.1, 116.7, 114.8, 114.0, 113.6, 112.4, 102.2, 55.8 ppm. HRMS (ESI) *m/z* calcd for C₂₂H₁₅N₂O₂ [M + H]⁺: 339.1128, found: 339.1122.

The general synthesis of heterocyclic iodoniums 1

All the synthetic heterocyclic iodoniums are reported in our previous work, and they are prepared conveniently using reported procedure.^{10,18}

11-Oxo-11*H*-benzo[*b*]chromeno[2,3-*d*]iodol-10-ium triflate (1a). ¹H NMR (400 MHz, DMSO) δ 8.50–8.35 (m, 2H), 8.22 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.11–8.02 (m, 2H), 8.01–7.91 (m, 2H), 7.72 (t, *J* = 7.5 Hz, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 172.3, 164.1, 155.2, 135.9, 135.2, 134.7, 131.4, 131.3, 128.9, 127.0, 125.2, 122.5, 119.6, 118.8, 108.4 ppm.

8-Methyl-11-oxo-10λ³-benzo[*b*]chromeno[2,3-*d*]iodol-10(11*H*)-yl trifluoromethanesulfonate (1b). ¹H NMR (400 MHz, DMSO) δ 8.31 (d, *J* = 8.0 Hz, 1H), 8.23 (s, 1H), 8.21 (dd, *J* = 8.0, 1.5 Hz, 1H), 8.03 (ddd, *J* = 8.6, 7.1, 1.7 Hz, 1H), 7.95 (d, *J* = 7.9 Hz, 1H), 7.88 (d, *J* = 7.7 Hz, 1H), 7.74–7.68 (m, 1H), 2.58 (s, 3H) ppm. ¹³C NMR (100 MHz, DMSO) δ 172.2, 164.0, 155.1, 146.2, 135.8, 132.5, 132.2, 131.2, 128.5, 126.9, 125.2, 122.4, 119.7, 118.7, 107.4, 21.8 ppm.

8-Chloro-11-oxo-10λ³-benzo[*b*]chromeno[2,3-*d*]iodol-10(11*H*)-yl trifluoromethanesulfonate (1c). ¹H NMR (400 MHz, DMSO) δ 8.42 (d, *J* = 1.8 Hz, 1H), 8.39 (d, *J* = 8.4 Hz, 1H), 8.21 (dd, *J* = 7.9, 1.2 Hz, 1H), 8.14 (dd, *J* = 8.4, 1.8 Hz, 1H), 8.07–8.00 (m, 1H), 7.95 (d, *J* = 8.3 Hz, 1H), 7.71 (t, *J* = 7.5 Hz, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 172.2, 163.2, 155.1, 138.5, 136.0, 134.3, 131.9, 131.3, 130.9, 129.8, 128.5, 127.1, 125.3, 122.5, 120.1, 118.8, 109.1 ppm.

8-Fluoro-11-oxo-10λ³-benzo[*b*]chromeno[2,3-*d*]iodol-10(11*H*)-yl trifluoromethanesulfonate (1d). ¹H NMR (400 MHz, DMSO) δ 8.50–8.44 (m, 1H), 8.22 (ddd, *J* = 8.0, 5.9, 2.3 Hz, 2H), 8.09–8.00 (m, 1H), 8.01–7.91 (m, 2H), 7.71 (dd, *J* = 10.6, 4.3 Hz, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 172.1, 165.2, 163.2, 162.7, 155.2, 136.0, 132.1, 130.8, 130.7, 127.1, 125.3, 122.5, 120.3, 120.2, 112.0, 119.7, 119.3, 119.0, 118.8, 108.5 ppm.

7-Fluoro-11-oxo-10λ³-benzo[*b*]chromeno[2,3-*d*]iodol-10(11*H*)-yl trifluoromethanesulfonate (1e). ¹H NMR (400 MHz, DMSO) δ 8.50–8.43 (m, 1H), 8.39 (dd, *J* = 5.6, 2.7 Hz, 1H), 8.23 (d, *J* = 7.9 Hz, 1H), 8.06 (t, *J* = 7.5 Hz, 1H), 7.95 (dd, *J* = 8.2, 2.3 Hz, 1H), 7.87 (ddd, *J* = 8.9, 6.2, 2.7 Hz, 1H), 7.73 (t, *J* = 6.2 Hz, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 172.3, 164.9, 163.0, 162.4, 155.1, 137.5, 137.4, 136.1, 133.7, 133.6, 127.1, 125.3, 122.4, 122.3, 122.0, 118.8, 115.9, 115.7, 113.6, 109.7 ppm.

11-Oxo-10λ³-benzo[*b*]thiochromeno[2,3-*d*]iodol-10(11*H*)-yl trifluoromethanesulfonate (1f). ¹H NMR (400 MHz, DMSO) δ 8.46 (t, *J* = 9.1 Hz, 2H), 8.34 (d, *J* = 7.8 Hz, 1H), 8.22 (d, *J* = 8.1 Hz, 1H), 8.04 (d, *J* = 7.6 Hz, 1H), 8.01–7.96 (m, 1H), 7.92 (t, *J* = 7.9 Hz, 1H), 7.87 (t, *J* = 7.6 Hz, 1H) ppm. ¹³C NMR (100

MHz, DMSO) δ 174.9, 150.6, 143.4, 135.8, 134.0, 132.1, 131.5, 129.7, 128.9, 128.8, 128.1, 128.0, 123.3, 122.8 ppm.

7*H*-7λ³-Benzo[4,5]iodolo[2,3-*c*]quinolin-7-yl tri-fluoromethanesulfonate (1g). To a stirred solution of 3-iodo-4-phenylquinoline **1g-I** (2.0 g, 6.04 mol) in anhydrous DCM (20 mL) was added TfOH (1.60 mL, 3.0 equiv.) and followed by the slow addition of *m*-CPBA (85%, 1.84 g, 1.5 equiv.). The solution was stirred for 2 h at rt before DCM was removed by rotary evaporation. Et₂O (20 mL) was added to the remained solid. The mixture was stirred for 30 min, and then filtered. The obtained solid was washed with Et₂O three times and dried in high *vacuo* to provide **1g** (2.43 g, 84% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO) δ 9.53 (s, 1H), 9.14 (d, *J* = 7.9 Hz, 1H), 9.09 (d, *J* = 8.8 Hz, 1H), 8.45 (d, *J* = 7.6 Hz, 1H), 8.30 (d, *J* = 7.9 Hz, 1H), 8.03 (t, *J* = 7.6 Hz, 2H), 7.97–7.86 (m, 2H) ppm. ¹³C NMR (100 MHz, DMSO) δ 148.6, 147.9, 144.8, 141.2, 132.4, 132.3, 131.2, 131.1, 131.1, 131.0, 130.6, 129.1, 126.4, 124.2, 123.9, 117.7 ppm.

9-Methyl-7*H*-7λ³-benzo[4,5]iodolo[2,3-*c*]quinolin-7-yl tri-fluoromethanesulfonate (1h). ¹H NMR (400 MHz, DMSO) δ 9.48 (s, 1H), 9.04 (d, *J* = 8.4 Hz, 1H), 8.99 (d, *J* = 8.4 Hz, 1H), 8.28 (dd, *J* = 8.4, 1.0 Hz, 1H), 8.20 (s, 1H), 8.02 (dd, *J* = 11.3, 4.0 Hz, 1H), 7.95–7.88 (m, 1H), 7.81 (d, *J* = 7.5 Hz, 1H), 2.56 (s, 3H) ppm. ¹³C NMR (100 MHz, DMSO) δ 148.4, 147.7, 144.8, 143.2, 138.4, 132.0, 131.9, 131.1, 131.0, 130.5, 129.0, 126.2, 124.2, 124.0, 122.4, 119.1, 117.0, 21.2 ppm.

9-Chloro-7*H*-7λ³-benzo[4,5]iodolo[2,3-*c*]quinolin-7-yl tri-fluoromethanesulfonate (1i). ¹H NMR (400 MHz, DMSO) δ 9.46 (s, 1H), 9.03 (d, *J* = 8.9 Hz, 1H), 8.94 (d, *J* = 8.5 Hz, 1H), 8.38 (d, *J* = 2.2 Hz, 1H), 8.27 (dd, *J* = 8.4, 1.1 Hz, 1H), 8.05–7.97 (m, 2H), 7.90 (ddd, *J* = 8.4, 7.0, 1.3 Hz, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 148.4, 147.9, 143.8, 140.1, 136.2, 133.2, 131.4, 130.7, 130.5, 129.3, 126.2, 124.9, 124.1, 122.4, 119.1, 118.2 ppm.

2-Fluoro-7*H*-7λ³-benzo[4,5]iodolo[2,3-*c*]quinolin-7-yl tri-fluoromethanesulfonate (1j). ¹H NMR (400 MHz, DMSO) δ 9.54 (d, *J* = 3.4 Hz, 1H), 9.15 (dd, *J* = 7.7, 2.7 Hz, 1H), 8.89–8.72 (m, 1H), 8.46 (dd, *J* = 8.1, 2.3 Hz, 1H), 8.40 (ddd, *J* = 9.3, 6.0, 3.4 Hz, 1H), 8.08–7.85 (m, 3H) ppm. ¹³C NMR (100 MHz, DMSO) δ 162.4, 159.9, 148.0, 145.3, 144.5, 144.4, 140.7, 133.7, 133.6, 132.4, 132.2, 131.2, 131.2, 127.0, 126.9, 123.7, 122.3, 121.2, 121.0, 119.1, 118.9, 108.8, 108.6 ppm.

Benzo[4,5]iodolo[3,2-*c*]isoquinolin-11-ium triflate (1k). ¹H NMR (400 MHz, DMSO) δ 9.73 (s, 1H), 8.59–8.51 (m, 2H), 8.43 (dd, *J* = 10.6, 8.3 Hz, 2H), 8.18–8.07 (m, 1H), 7.97 (t, *J* = 7.5 Hz, 2H), 7.90–7.81 (m, 1H) ppm. ¹³C NMR (100 MHz, DMSO) δ 155.6, 153.4, 140.6, 134.5, 133.6, 132.6, 131.1, 130.7, 130.1, 129.5, 129.3, 126.7, 122.3, 121.4, 120.5 ppm.

9-Methyl-11*H*-11λ³-benzo[4,5]iodolo[3,2-*c*]isoquinolin-11-yl trifluoromethanesulfonate (1l). ¹H NMR (400 MHz, DMSO) δ 9.58 (s, 1H), 8.40 (d, *J* = 8.2 Hz, 1H), 8.34 (d, *J* = 8.1 Hz, 1H), 8.24 (d, *J* = 7.9 Hz, 1H), 8.07 (s, 1H), 8.06–8.01 (m, 1H), 7.89 (t, *J* = 7.3 Hz, 1H), 7.66 (d, *J* = 7.8 Hz, 1H), 2.51 (s, 3H) ppm. ¹³C NMR (100 MHz, DMSO) δ 155.4, 153.2, 143.2, 137.8, 134.3, 133.5, 132.0, 130.2, 129.8, 129.4, 129.2, 128.6, 126.4, 121.2, 119.5, 21.5 ppm.

6-Oxo-7λ³-benzo[*b*]chromeno[4,3-*d*]iodol-7(6*H*)-yl tri-fluoromethanesulfonate (1m). ¹H NMR (400 MHz, DMSO) δ 9.12–9.02 (m, 1H), 8.81 (d, *J* = 7.5 Hz, 1H), 8.53 (dd, *J* = 8.3,



1.0 Hz, 1H), 8.10–8.01 (m, 1H), 8.00–7.93 (m, 1H), 7.92–7.85 (m, 1H), 7.71 (dd, $J = 8.3, 0.9$ Hz, 1H), 7.66–7.56 (m, 1H) ppm. ^{13}C NMR (100 MHz, DMSO) δ 157.2, 153.6, 152.7, 141.0, 133.5, 133.4, 133.0, 132.2, 131.4, 126.2, 125.6, 125.2, 118.2, 117.9, 117.3 ppm.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful to the grant support from National Natural Science Foundation of China (81672952, 81872440), Guangdong Science and Technology Program (2017A020215198, 2018A030310240), and Guangzhou Science and Technology Program (201807010041).

Notes and references

- (a) H. Ito, K. Ozaki and K. Itami, *Angew. Chem. Int. Ed.*, 2017, **56**, 11144–11164; *Angew. Chem.*, 2017, **129**, 11296–11317; (b) J. Mei, N. L. C. Leung, R. T. K. Kwok, J. W. Y. Lam and B. Z. Tang, *Chem. Rev.*, 2015, **115**, 11718–11940.
- D. A. Erlanson, S. W. Fesik, R. E. Hubbard, W. Jahnke and H. Jhoti, *Nat. Rev. Drug Discovery*, 2016, **15**, 605–619.
- (a) G. B. Deng, Z. Q. Wang, J. D. Xia, P. C. Qian, R. J. Song, M. Hu, L. B. Gong and J. H. Li, *Angew. Chem. Int. Ed.*, 2013, **52**, 1535–1538; *Angew. Chem.*, 2013, **125**, 1575–1578; (b) J. H. Kim, J. Bouffard and S. G. Lee, *Angew. Chem. Int. Ed.*, 2014, **53**, 6435–6438; *Angew. Chem.*, 2014, **126**, 6553–6556; (c) J. H. Kim, Y. O. Ko, J. Bouffard and S. G. Lee, *Chem. Soc. Rev.*, 2015, **44**, 2489–2507; (d) Y. Liu and J.-P. Wan, *Org. Biomol. Chem.*, 2011, **9**, 6873–6894.
- M. Wang, Q. Fan and X. Jiang, *Org. Lett.*, 2018, **20**, 216–219.
- (a) Y. Wu, X. Peng, B. Luo, F. Wu, B. Liu, F. Song, P. Huang and S. Wen, *Org. Biomol. Chem.*, 2014, **12**, 9777–9780; (b) D. Zhu, Q. Liu, B. Luo, M. Chen, R. Pi, P. Huang and S. Wen, *Adv. Synth. Catal.*, 2013, **355**, 2172–2178.
- (a) X. Peng, H. Luo, F. Wu, D. Zhu, A. Ganesan, P. Huang and S. Wen, *Adv. Synth. Catal.*, 2017, **359**, 1152–1156; (b) D. Zhu, Y. Wu, B. Wu, B. Luo, A. Ganesan, F. H. Wu, R. Pi, P. Huang and S. Wen, *Org. Lett.*, 2014, **16**, 2350–2353.
- Z. Liu, D. Zhu, B. Luo, N. Zhang, Q. Liu, Y. Hu, R. Pi, P. Huang and S. Wen, *Org. Lett.*, 2014, **16**, 5600–5603.
- (a) D. Zhu, M. Li, Z. Wu, Y. Du, B. Luo, P. Huang and S. Wen, *Eur. J. Org. Chem.*, 2019, 4566–4571; (b) B. Luo, Q. Cui, H. Luo, Y. Hu, P. Huang and S. Wen, *Adv. Synth. Catal.*, 2016, **358**, 2733–2738; (c) Q. Tan, D. Zhou, T. Zhang, B. Liu and B. Xu, *Chem. Commun.*, 2017, **53**, 10279–10282; (d) M. Wang, J. Wei, Q. Fan and X. Jiang, *Chem. Commun.*, 2017, **53**, 2918–2921; (e) P. S. Postnikov, O. A. Guselnikova, M. S. Yusubov, A. Yoshimura, V. N. Nemykin and V. V. Zhdankin, *J. Org. Chem.*, 2015, **80**, 5783–5788; (f) Y. A. Vlasenko, P. S. Postnikov, M. E. Trusova, A. Shafir, V. V. Zhdankin, A. Yoshimura and M. S. Yusubov, *J. Org. Chem.*, 2018, **83**, 12056–12070.
- J. Letessier and H. Detert, *Synthesis*, 2012, **44**, 290–296.
- D. Zhu, Z. Wu, B. Luo, Y. Du, P. Liu, Y. Chen, Y. Hu, P. Huang and S. Wen, *Org. Lett.*, 2018, **20**, 4815–4818.
- (a) S. U. Dighe, S. Khan, I. Soni, P. Jain, S. Shukla, R. Yadav, P. Sen, S. M. Meeran and S. Batra, *J. Med. Chem.*, 2015, **58**, 3485–3499; (b) T. K. Mazu, J. R. Etukala, M. R. Jacob, S. I. Khan, L. A. Walker and S. Y. Ablordeppey, *Eur. J. Med. Chem.*, 2011, **46**, 2378–2385; (c) G. Van Baelen, S. Hostyn, L. Dhooche, P. Tapolcsányi, P. Mátyus, G. Lemièr, R. Dommissie, M. Kaiser, R. Brun, P. Cos, L. Maes, G. Hajós, Z. Riedl, I. Nagy, B. U. W. Maes and L. Pieters, *Bioorg. Med. Chem.*, 2009, **17**, 7209–7217.
- (a) J. Reis, A. Gaspar, N. Milhazes and F. Borges, *J. Med. Chem.*, 2017, **60**, 7941–7957; (b) R. S. Keri, S. Budagumpi, R. K. Pai and R. G. Balakrishna, *Eur. J. Med. Chem.*, 2014, **78**, 340–374.
- (a) Shaveta, S. Mishra and P. Singh, *Eur. J. Med. Chem.*, 2016, **124**, 500–536; (b) C. de Bodinat, B. Guardiola-Lemaitre, E. Mocaer, P. Renard, C. Munoz and M. J. Millan, *Nat. Rev. Drug Discovery*, 2010, **9**, 628–642; (c) F. H. Havaladar, S. Bhise and S. Burudkar, *J. Serb. Chem. Soc.*, 2004, **69**, 527–532; (d) L. Duan, J. Qiao, Y. Sun and Y. Qiu, *Adv. Mater.*, 2011, **23**, 1137–1144.
- (a) Y. Wei, P. Hu, M. Zhang and W. Su, *Chem. Rev.*, 2017, **117**, 8864–8907; (b) N. Rodriguez and L. Goossen, *Chem. Soc. Rev.*, 2011, **40**, 5030–5048.
- (a) S. Yang, F. Wang, Y. Wu, W. Hua and F. Zhang, *Org. Lett.*, 2018, **20**, 1491–1495; (b) S. Yang, W. Hua, Y. Wu, T. Hu, F. Wang, X. Zhang and F. Zhang, *Chem. Commun.*, 2018, **54**, 3239–3242.
- (a) S. Sergeyev, W. Pisulab and Y. Geerts, *Chem. Soc. Rev.*, 2007, **36**, 1902–1929; (b) S. Laschat, A. Baro, N. Steinke, F. Giesselmann, C. Hgele, G. Scalia, R. Judele, E. Kapatsina, S. Sauer, A. Schreivogel and M. Tosoni, *Angew. Chem. Int. Ed.*, 2007, **46**, 4832–4887; *Angew. Chem.*, 2007, **119**, 4916–4973.
- J. Wei, B. Han, Q. Guo, X. Shi, W. Wang and N. Wei, *Angew. Chem. Int. Ed.*, 2010, **49**, 8209–8213; *Angew. Chem.*, 2010, **122**, 8385–8389.
- (a) C. Zhou, A. Dubrovsky and R. Larock, *J. Org. Chem.*, 2006, **71**, 1626–1632; (b) Q. Huang, J. Hunter and R. Larock, *J. Org. Chem.*, 2002, **67**, 3437–3444; (c) M. Reddy, N. Thirupathi, M. Babu and S. Puri, *J. Org. Chem.*, 2013, **78**, 5878–5888.

